These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36279685)

  • 1. Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.
    Morales-Núñez JJ; Muñoz-Valle JF; Machado-Sulbarán AC; Díaz-Pérez SA; Torres-Hernández PC; Panduro-Espinoza BV; Gallegos-Díaz de Leon JA; Munguía-Ramirez CD; Hernández-Bello J
    Immunol Lett; 2022 Dec; 251-252():20-28. PubMed ID: 36279685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.
    Muena NA; García-Salum T; Pardo-Roa C; Avendaño MJ; Serrano EF; Levican J; Almonacid LI; Valenzuela G; Poblete E; Strohmeier S; Salinas E; Muñoz A; Haslwanter D; Dieterle ME; Jangra RK; Chandran K; González C; Riquelme A; Krammer F; Tischler ND; Medina RA
    EBioMedicine; 2022 Apr; 78():103972. PubMed ID: 35366624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2.
    Hernández-Bello J; Morales-Núñez JJ; Machado-Sulbarán AC; Díaz-Pérez SA; Torres-Hernández PC; Balcázar-Félix P; Gutiérrez-Brito JA; Lomelí-Nieto JA; Muñoz-Valle JF
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19.
    Zheng H; Li C; Zheng X; Jiang HD; Li Y; Yao A; Li X; Wang F; Liu W; Cao X; Qi R; Chen L; Jin L; Zhu F; Li J; Chen F
    Front Immunol; 2024; 15():1461419. PubMed ID: 39328415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
    Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.
    Tang R; Zheng H; Wang BS; Gou JB; Guo XL; Chen XQ; Chen Y; Wu SP; Zhong J; Pan HX; Zhu JH; Xu XY; Shi FJ; Li ZP; Liu JX; Zhang XY; Cui LB; Song ZZ; Hou LH; Zhu FC; Li JX;
    Lancet Respir Med; 2023 Jul; 11(7):613-623. PubMed ID: 36898400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults.
    Zhang H; Xu N; Xu Y; Qin P; Dai R; Xu B; Wang S; Ding L; Fu J; Zhang S; Hua Q; Liao Y; Yang J; Hu X; Jiang J; Lv H
    Nat Commun; 2023 Aug; 14(1):4757. PubMed ID: 37553338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial.
    Jin L; Tang R; Wu S; Guo X; Huang H; Hou L; Chen X; Zhu T; Gou J; Zhong J; Pan H; Cui L; Chen Y; Xia X; Feng J; Wang X; Zhao Q; Xu X; Li Z; Zhang X; Chen W; Li J; Zhu F
    Emerg Microbes Infect; 2023 Dec; 12(1):2155251. PubMed ID: 36503413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.
    Li JX; Wu SP; Guo XL; Tang R; Huang BY; Chen XQ; Chen Y; Hou LH; Liu JX; Zhong J; Pan HX; Shi FJ; Xu XY; Li ZP; Zhang XY; Cui LB; Tan WJ; Chen W; Zhu FC;
    Lancet Respir Med; 2022 Aug; 10(8):739-748. PubMed ID: 35605625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.
    Wang F; Huang B; Deng Y; Zhang S; Liu X; Wang L; Liu Q; Zhao L; Tang L; Wang W; Wang X; Ye F; Hu W; Yang H; Wang S; Ren J; Liu X; Wang C; Guan X; Wang R; Zheng Y; Zhang X; Zheng H; Wu D; An Z; Xu W; Rodewald LE; Gao GF; Yin Z; Tan W
    BMC Med; 2023 Jul; 21(1):233. PubMed ID: 37400857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study.
    Kuloğlu ZE; El R; Guney-Esken G; Tok Y; Talay ZG; Barlas T; Kuskucu MA; Albayrak Ö; Doğan Ö; Yavuz SŞ; Midilli K; Ergönül Ö; Can F
    Allergy; 2022 Aug; 77(8):2459-2467. PubMed ID: 35437772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
    Assawakosri S; Kanokudom S; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Yorsaeng R; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Honsawek S; Poovorawan Y
    J Infect Dis; 2022 Oct; 226(8):1372-1381. PubMed ID: 35267040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients.
    Zhang Z; Wu S; Liu Y; Li K; Fan P; Song X; Wang Y; Zhao Z; Zhang X; Shang J; Zhang J; Xu J; Li Y; Li Y; Zhang J; Fu K; Wang B; Hao M; Zhang G; Long P; Qiu Z; Zhu T; Liu S; Zhang Y; Shao F; Lv P; Yang Y; Zhao X; Sun Y; Hou L; Chen W
    Front Immunol; 2023; 14():1239179. PubMed ID: 37868993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile.
    Acevedo J; Acevedo ML; Gaete-Argel A; Araos R; Gonzalez C; Espinoza D; Rivas S; Pizarro P; Jarpa S; Soto-Rifo R; Jara A; Valiente-Echeverría F
    Clin Microbiol Infect; 2023 Apr; 29(4):541.e1-541.e7. PubMed ID: 36436704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.
    Xu JW; Wang BS; Gao P; Huang HT; Wang FY; Qiu W; Zhang YY; Xu Y; Gou JB; Yu LL; Liu X; Wang RJ; Zhu T; Hou LH; Wang Q
    Emerg Microbes Infect; 2024 Dec; 13(1):2281355. PubMed ID: 37933089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population.
    Hernández-Bello J; Lorenzo-Leal AC; Muñoz-Valle JF; Morales-Núñez JJ; Díaz-Pérez SA; Hernández-Gutiérrez R; Bach H
    PLoS One; 2024; 19(4):e0299520. PubMed ID: 38573914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study.
    Xu N; Xu Y; Dai R; Zheng L; Qin P; Wan P; Yang Y; Jiang J; Zhang H; Hu X; Lv H
    Front Immunol; 2023; 14():1244373. PubMed ID: 37736100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.
    Lioznov D; Amosova I; Sheetikov SA; Zornikova KV; Serdyuk Y; Efimov GA; Tsyferov M; Khmelevskii M; Afanasiev A; Khomyakova N; Zubkov D; Tikhonov A; Zhu T; Barreto L; Dzutseva V
    PLoS One; 2023; 18(3):e0278878. PubMed ID: 36888640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
    Nooka AK; Shanmugasundaram U; Cheedarla N; Verkerke H; Edara VV; Valanparambil R; Kaufman JL; Hofmeister CC; Joseph NS; Lonial S; Azeem M; Manalo J; Switchenko JM; Chang A; Linderman SL; Roback JD; Dhodapkar KM; Ahmed R; Suthar MS; Neish AS; Dhodapkar MV
    J Clin Oncol; 2022 Sep; 40(26):3057-3064. PubMed ID: 35259002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.